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More than 240 million people worldwide are infected with
hepatitis B virus (HBV) and are at risk of developing liver cirrhosis
and hepatocellular carcinoma (HCC). Reducing this pool of
infected people is a necessity since despite an effective prophylactic
vaccine, about 2% of the vaccinated individuals in high endemic
areas still develop chronic HBV infection (CHB). A battery of
antiviral drugs based on nucleoside or nucleotide analogues that
target the HBV reverse transcriptase are available. They efficiently
suppress HBV replication and reduce liver inflammation linked
with cirrhosis but rarely achieve virus eradication. HBV is present
in hepatocytes in a mini-chromosomal form (called cccDNA) that
is untouched by reverse transcriptase inhibitors. As a consequence,
response to the treatment is hardly durable and a majority of
patients experience HBV reactivation when antiviral therapy is
withdrawn [1]. Failure to achieve sustained control of HBV
infection is linked with an inability to elicit an effective immune
response that resembles one present in adult patients that resolve
acute infection. However, since HBV is a non-cytopathic virus,
immunological processes are also responsible for the chronic
inflammatory events that cause cirrhosis and HCC [1]. Immuno-
therapeutic approaches primarily designed to control viral
replication through the boosting of antiviral immunity or that
aim to inhibit the liver inflammatory processes linked with
cirrhosis and HCC development will be discussed.
What Is the Immunological Profile of HBV
Control?
Efficient control of HBV infection is associated with the
induction and persistence of helper and cytotoxic T cells targeting
different HBV proteins and production of anti-HBV envelope
antibodies. This antiviral immune response is composed of T cells
able to secrete Th1 cytokines, proliferate and lyse HBV infected
hepatocytes [1], and it is induced almost exclusively in adult
patients after acute HBV infection. Chronic HBV patients fail to
mount such an efficient antiviral response. HLA-class II genetic
profile [2], dose of virus [3], and age at infection [4] influence the
induction of a protective antiviral immunity, but a detailed
discussion of the causes of HBV chronicity exceeds the focus of this
brief review. What has instead been clearly demonstrated in
animal models and in natural infection is that HBV-specific
adaptive immunity occurs in the context of a peculiar innate
immune response. This response is delayed four to six weeks post
infection when HBV replication has already reached extremely
high levels (.106 copies/ml) [1]. Innate immune activation is
characterized by large production of IFN-c rather than IFN-a/b
[5]. Indeed, while HBV doesn’t trigger high IFN-a production and
also interferes with its antiviral effect [6,7], a robust IFN-c
production precedes the detection of HBV-specific T cells in acute
HBV and correlates with a significant drop in HBV replication
and HBV antigens [5]. The innate immune cell components
responsible for HBV sensing and IFN-c production and ultimately
induction of protective adaptive immunity have not been defined
during natural infection [1]. Elegant work in mice showed that
CD1-restricted NKT cells are activated by self-lipids induced by
HBV replication [8], but in addition to the fact that HBV
replication in this mouse model was mediated by an adenoviral
vector, CD1-restricted NKT cells are abundant in mouse but not
in human livers [9]. In human, the network of innate lymphocytes
resident in the liver is mainly composed of NK CD56 bright cells
and mucosal-associated invariant T (MAIT) cells that can produce
large quantities of IFN-c through cytokine-mediated (IL-12, IL-18)
activation [10]. Activation of these innate cells might therefore be
necessary for the successful control of HBV infection, but further
studies are necessary to precisely define their role in the early stage
of infection.
What Can Be the Strategies to Restore Adaptive
Immunity in Chronic HBV Patients?
After years of exposure to HBV antigens, HBV-specific T cells
are deleted or functionally exhausted in chronic patients. Virus-
specific T cells express inhibitory molecules like PD-1 [11], CTLA-
4 [12], SLAM [13], and TIM-3 [14,15] and are defective in
proliferation and cytokine production. Blocking inhibitory path-
ways, new aggressive vaccination regimens and experimental gene
therapy strategies have been proposed to rebuild a functional
HBV-specific T cell response in these patients (Figure 1).
Blocking inhibitory pathways associated with T cell exhaustion
has shown therapeutic efficacy in cancer patients [16]. Interfering
with these pathways can also achieve partial functional recovery of
HBV-specific T cells from CHB patients in vitro, but we still lack
data in vivo evaluating the efficacy of this approach in CHB
patients [16].
Vaccine therapy aims to induce functionally efficient HBV-
specific T cells on the background of virus-specific T cell
exhaustion. Several strategies have been tested in clinical trials
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with disappointing results. Often, vaccine therapy did not induce
an HBV-specific T cell response, or when such response was
boosted, it did not have a therapeutic effect [17]. However, it was
recently demonstrated that the use of new highly immunogenic
vaccine preparations in combination with antiviral treatment
showed immunological and therapeutic efficacy in the woodchuck
model of chronic HBV infection [18]. In addition, intriguing data
was reported from a phase III clinical trial of a therapeutic
vaccine. A significant virological response was observed in 20% of
patients treated not only with the vaccine but also with adjuvant
alone [19]. The immunological mechanisms responsible were not
characterized but plausible hypotheses can be derived from recent
studies. Intrahepatic activation of the myeloid compartment with
TLR agonists [20] results in effective T cell expansion in murine
systems. Agonistic anti-CD40 [21] activation of dendritic cells
rescues naı¨ve CD8 T cell priming to antigens produced in the liver
of HBV transgenic mice, which is otherwise aborted by PD-1/PD-
L1 interactions. These data together with our recent demonstra-
tion that monocytes internalize HBV antigens in the circulation of
chronic patients and activate autologous HBV-specific T cells after
maturation with inflammatory stimuli [22] suggest that repetitive
injections of adjuvants alone could induce the inflammatory
environment capable of stimulating intrahepatic HBV-specific T
cells (Figure 2). This could provide a clear advantage to current
vaccines that use a single recombinant antigen and do not account
for the 8% of genetic diversity among HBV genotypes [23].
Capitalizing on the antigen present in infected patients could
provide the full repertoire of antigens personalized to the infecting
virus. If this can be confirmed in vivo, CHB vaccine therapy could
be performed using adjuvants alone and the ‘‘personalized
antigenic depot’’ within the patients to overcome the problem of
viral diversity.
However, more radical approaches could be needed to
circumvent HBV-specific T cell deletion in patients with high
viral loads. Engineering HBV-specific T cells through transfer of
HBV-specific T cell receptors or HBV-specific chimeric antigen
receptors (CAR) showed encouraging results in vitro and in animal
models [24,25]. The concept of adoptively transferring a
functionally efficient HBV-specific immune system is not new in
HBV. CHB patients receiving bone marrow transplants from
HBV-immune donors were cured. Likewise, HBV+ livers trans-
planted in HBV-immune donors resulted in viral control [17].
Thus, gene therapy approaches might have potential, but safety
concerns, cost, and ethical issues related to viral vector use need to
be addressed.
Several other factors have also hampered the restoration of
efficient adaptive immunity in CHB. Epigenetic programs were
suggested to preserve the T cell exhaustion state in chronic viral
infection [26]. Also, in many CHB patients, HBV-specific T cells
are not only dysfunctional but can be physically deleted, adding
obstacles to vaccination approaches. Furthermore, IL-10 [16],
TGF-b [27], arginase [28], and T regulatory cells [29] are
increased in the chronically inflamed livers. Even if it is possible to
genetically engineer HBV-specific immunity, the suppressive
microenvironment could hinder HBV clearance.
The duration of exposure and antigen burden in chronic HVB
infection are believed to be the primary factors affecting
virus-specific T cell function. Thus, modulating the quantity of
Figure 1. Different immune-based therapeutic strategies aiming to increase HBV control.
doi:10.1371/journal.ppat.1003784.g001
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viral antigens secreted by HBV might have a beneficial effect as
has been observed in HBV transgenic mice [30]. It should also be
considered that adolescent and young CHB patients display a less
compromised HBV-specific antiviral immune response than their
adult counterparts [31]; therefore, they may be more responsive to
immunotherapeutic strategies.
How Can We Directly Stimulate Intrahepatic
Innate Immunity?
The important role played by innate immunity in the early
stages of infection has stimulated therapeutic strategies to
specifically target this branch. IFN-a therapeutic efficacy is
associated with NK cell activation [32]. Therefore, increasing
intrahepatic IFN-a levels could be clinically beneficial (Figure 1).
In one approach, we have developed T cell receptor–like
antibodies conjugated with IFN-a that specifically target HBV-
infected hepatocytes to increase intrahepatic IFN-a delivery
[33].
Other approaches in clinical development seek to induce
intrahepatic IFN-a production through oral administration of
TLR agonists. TLR7 agonists stimulate robust IFN-a production
in plasmacytoid dendritic cells. However, prolonged efficacy in
TLR-7 agonist–treated, HBV-infected chimpanzees was not only
related to the production of IFN-a, as its production was transient
and not liver specific. Antiviral efficacy was more consistent with a
boost of intrahepatic NK, NKT, and T cell responses associated
with production of IFN-c [34]. Since, as reported previously,
intrahepatic NK and MAIT cells can be activated by IL-12 and
IL-18 cytokines [10], TLR agonists triggering IL-12 and IL-18
hepatic secretion might be particularly important. These cytokines
selectively activate innate immune cells within the liver compart-
ment and can induce partial functional recovery of exhausted
HBV-specific CD8+ T cells [35].
Is the Reduction of Liver Inflammation a Valuable
Therapeutic Strategy for CHB Infection?
The immunotherapeutic strategies we reviewed aim to control
HBV infection by increasing antiviral immunity and as such
terminate the chronic inflammatory process. However, activation
of intrahepatic adaptive or innate cellular immunity requires tight
control because it could also exacerbate liver inflammation. Even
though mechanisms like IL-10 production, release of arginase
from hepatocytes, and even the dampening of T cell responses by
activated NK cells [36] are in place to control excessive activation
of intrahepatic immunity, hepatocyte lysis and increased IFN-c
production can still trigger inflammatory chemokines (e.g.,
CXCL10) responsible for recruiting inflammatory cells (macro-
phages, non-HBV-specific T cells) that cause the bulk of liver
damage [1].
A radically different perspective in chronic HBV treatment is to
consider CHB a necro-inflammatory rather than viral disease.
Recent data in HBV transgenic mice clearly indicate that
suppressing intrahepatic CTL activity in the liver using anti-
platelet therapy prevents hepatocellular carcinoma. Platelets
promote the accumulation of CD8 T cells in the liver and anti-
platelet therapy blocks this process, reducing hepatocellular injury
and fibrosis [37]. In addition to these experimental data,
observations that HBsAg quantity is associated with liver fibrosis
protection [38] introduced a further level of uncertainty about the
beneficial effect of HBV suppression.
In conclusion, the current immunotherapeutic strategies
designed to suppress and control HBV replication have strong
scientific support. However, they are restricted by our limited
knowledge, and further understanding of the relationship with the
virus in the unique environment of the human liver will almost
certainly provide opportunities to enhance them or perhaps
develop totally novel approaches.
Figure 2. Schematic representation of the potential ability of HBV-loaded monocytes [22] to stimulate HBV-specific T cells trough
TLR [20] or anti-CD40 agonists [21]. MN=monocytes, DC=dendritic cells.
doi:10.1371/journal.ppat.1003784.g002
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